Prevention of chronic renal allograft rejection by soluble CD83

Transplantation

Volumn 90, Issue 12, 2010, Pages 1278-1285

  Lan, Zhu ^a   Lian, Dameng ^a   Liu, Weihua ^a,b   Arp, Jacqueline ^a   Charlton, Brayden ^a   Ge, Wei ^a   Brand, Stephen ^c   Healey, Don ^c   Debenedette, Mark ^c   Nicolette, Charles ^c   Garcia, Bertha ^a   Wang, Hao ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c Argos Therapeutics Inc   (United States)

Author keywords

Alloantibody; Chronic rejection; Cytokine; Kidney transplantation; Soluble CD83

Indexed keywords

CD83 ANTIGEN; CYCLOSPORIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; SOLUBLE CD83 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC RENAL ALLOGRAFT REJECTION; CONTROLLED STUDY; DENDRITIC CELL; FIBROSING ALVEOLITIS; FISCHER 344 RAT; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MONOCYTE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD; CYCLOSPORINE; CYTOKINES; DOWN-REGULATION; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MEMBRANE GLYCOPROTEINS; MICE; MYELOID DIFFERENTIATION FACTOR 88; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650830316     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318200005c     Document Type: Article

References (20)

1. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
2. U.S. Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-.2007. Rockville, MD, U.S. Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation 2008.
3. Furness PN. Histopathology of chronic renal allograft dysfunction. Transplantation 2001; 71(11 suppl): SS31.
4. Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2008; 17: 149.
5. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
6. Riteau B, Rouas-Freiss N, Menier C, et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001; 166: 5018.
7. Bedard EL, Jiang J, Arp J, et al. Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation 2006; 81: 908.
8. Zhou LJ, Schwarting R, Smith HM, et al. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 1992; 149: 735.
9. Hock BD, Kato M, McKenzie JL, et al. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 2001; 13: 959.
10. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995; 154: 3821.
11. Scholler N, Hayden-Ledbetter M, Dahlin A, et al. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 2002; 168: 2599.
12. Prazma CM, Yazawa N, Fujimoto Y, et al. CD83 expression is a sensitive marker of activation required for B cell and CD4- T cell longevity in vivo. J Immunol 2007; 179: 4550.
13. Kruse M, Rosorius O, Kratzer F, et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 2000; 74: 7127.
14. Salio M, Cella M, Suter M, et al. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999; 29: 3245.
15. Prechtel AT, Turza NM, Theodoridis AA, et al. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol 2007; 178: 5454.
16. Hirano N, Butler MO, Xia Z, et al. Engagement of CD83 ligand induces prolonged expansion of CD8- T cells and preferential enrichment for antigen specificity. Blood 2006; 107: 1528.
17. Fujimoto Y, Tu L, Miller AS, et al. CD83 expression influences CD4- T cell development in the thymus. Cell 2002; 108: 755.
18. Kretschmer B, Luthje K, Schneider S, et al. Engagement of CD83 on B cells modulates B cell function in vivo. J Immunol 2009; 182: 2827.
19. Prazma CM, Tedder TF. Dendritic cell CD83: A therapeutic target or innocent bystander? Immunol Lett 2008; 115: 1.
20. Breloer M, Kretschmer B, Luthje K, et al. CD83 is a regulator of murine B cell function in vivo. Eur J Immunol 2007; 37: 634.